Opendata, web and dolomites

RV001 SIGNED

RV001: An anti-metastatic cancer vaccine

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "RV001" data sheet

The following table provides information about the project.

Coordinator
RHOVAC APS 

Organization address
address: AGERN ALLE 24 1
city: HORSHOLM
postcode: 2970
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Total cost 5˙273˙880 €
 EC max contribution 2˙499˙900 € (47%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2022-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RHOVAC APS DK (HORSHOLM) coordinator 2˙499˙900.00

Map

 Project objective

Prostate cancer is the most commonly diagnosed cancer in men, with 1.7M new cases and 0.5M deaths anticipated by 2030 worldwide. Although metastases are responsible in 90% of cancer deaths, in today’s standard treatment there is no active therapy after removal of primary tumor to prevent metastasis formation. 40% of patients experience relapse of cancer in the first 2 years after surgery. The existing treatments focusing on later stages, do not prevent the initial spread of metastatic cells and cause numerous undesirable side effects. Late stage immunotherapies against metastatic cancer also present major drawbacks, including high costs and adverse events. So, there is a critical unmet need for a therapy that can effectively prevent metastasis formation in early stage prostate cancer. RhoVac aims to address this need by developing the first therapeutic vaccine against early stage metastases in prostate cancer – RV001 – which could revolutionize the treatment of metastatic cancer. Through the activation of the patient’s own immune system, RhoVac projects that RV001 will induce the specific elimination of metastatic cancer cells with unprecedented levels of safety, tolerability and biological activity, proven with the successful conclusion of a Phase I/II clinical trial in 2018. RhoVac aims to develop the RV001 vaccine up to completion of a Phase IIb clinical trial (key objective of the present project), following which the company plans to out-license the vaccine to a large Pharma, with conservatively predicted revenues of ca. €1B, within 5 years of vaccine launch. Due to its mechanism, RV001 could potentially be used against all metastatic cancer types. RhoVac will seek to validate this exploratively in parallel with the prostate cancer project. In short, our aim to introduce “metastatic prevention” as new paradigm in cancer treatment, rather than relying on the frequently ineffective treatment of metastases that have already formed.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RV001" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RV001" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

PrasinoMed (2018)

First in the world ecological and sustainable cream for wound care, based on microalgaprasinococcus capsulatus

Read More  

GREEN WHS (2019)

NATURE FRIENDLY WATER HYDRAULIC STEERING SYSTEM

Read More  

ChromicGlass (2019)

FAST-RESPONSIVE and LONG-LASTING TRANSPARENT PHOTOCHROMIC FILMS

Read More